Table 2.
Clinical characteristics of 22 patients relapsed after Haplo-HSCT with PTCy.
| HLA-loss relapses (n = 6) | % | Classical relapses (n = 16) | % | P-value | |||
|---|---|---|---|---|---|---|---|
| Diagnosis | AML | 1 | 16 | 9 | 56 | 0.64 | |
| MDS | 1 | 16 | |||||
| DCL | 1 | 16 | |||||
| ALL-B | 3 | 18 | |||||
| ALL-T | 1 | 16 | |||||
| HL | 2 | 33 | 1 | 6 | |||
| NHL | 3 | 18 | |||||
| Age (years) (Median, range) | 45 (27–55) | 31 (17–65) | 0.28 | ||||
| Recipient Sex (Female/Male) | 4/2 | 66/33 | 6/10 | 37/62 | 0.35 | ||
| Donor Sex (Female/Male) | 3/3 | 50/50 | 11/5 | 68/31 | 0.62 | ||
| Previous HSCT | Allogeneic | 2 | 33 | 2 | 12 | 0.63 | |
| Autologous | 1 | 16 | 2 | 12 | |||
| Treatment lines pre-HSCT | ≤2 | 2 | 33 | 13 | 81 | 0.06 | |
| >2 | 4 | 66 | 3 | 18 | |||
| Status at transplant | Active disease | 1 | 16 | 3 | 18 | 0.89 | |
| Partial Response | 3 | 50 | 4 | 25 | |||
| Complete Remission | 2 | 33 | 9 | 56 | |||
| Conditioning regimen | Myeloablative | 3 | 50 | 9 | 56 | 0.92 | |
| Non-Myeloablative | 3 | 50 | 7 | 43 | |||
| Time from HSCT to relapse (days) (Median, range) | 345 (88–570) | 166 (48–1458) | 0.15 | ||||
| GVHD before relapse | Acute | Grade I | 2 | 33 | 3 | 18 | 0.35 |
| Grade II | 1 | 16 | 3 | 18 | |||
| Grade III | 1 | 16 | 2 | 12 | |||
| Chronic | Mild | 1 | 16 | 2 | 12 | 0.58 | |
| Moderate | - | - | - | - | |||
| Severe | - | - | 1 | 6 | |||
ALL-B, B-cell acute lymphoblastic leukemia; ALL-T, T-cell acute lymphoblastic leukemia; AML, acute myeloid leukemia; DCL, dendritic cell leukemia; GVHD, graft-vs.-host disease; HL, hodgkin's lymphoma; HSCT, hematopoietic stem cell transplantation; MDS, myelodysplastic syndrome; NHL, non-hodgkin's lymphoma.